Telavancin

Edina Avdic, Pharm.D., Paul A. Pham, Pharm.D. BCPS
Pediatric Dosing Author: Alice Jenh Hsu, PharmD, BCPS, AQ-ID
Telavancin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
  • HAP and VAP caused by susceptible isolates of S. aureus.
    • It should be reserved for use when alternative agents are not suitable.

NON-FDA APPROVED USES

  • S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
  • HAP and VAP caused by susceptible isolates of S. aureus.
    • It should be reserved for use when alternative agents are not suitable.

NON-FDA APPROVED USES

  • S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 2, 2018